Journals / Journal of Clinical and Analytical Medicine / 2015 / Cilt: 6 - Sayı: 4

Goodpasture Sendromu Nedeniyle Alveolar Hemoraji Gelişen Bir Olguda Noninvaziv Pozitif Basınçlı Ventilasyon Kullanımı

Use Of Noninvazive Positive Pressure Ventilation in a Case of Diffuse Alveolar Hemorrhage Due to Goodpasture's Syndrome

Pages
504–506
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, the current case showed that Goodpasture s syndrome may have a favorable prognosis with early diagnosis and proper treatments including NPPV.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Antiglomerular basement membrane antibody disease is manifested by progressive glomerulonephritis, intraalveolar hemorrhage and antiglomerular basement membrane antibodies.
📊
Key Findings & Data:We present a case of a 18 year-old young showing remission by early diagnosis.
💡
Conclusion & Impact:In conclusion, the current case showed that Goodpasture s syndrome may have a favorable prognosis with early diagnosis and proper treatments including NPPV.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Antiglomerular basement membrane antibody disease is manifested by progressive glomerulonephritis, intraalveolar hemorrhage and antiglomerular basement membrane antibodies. It is frequently characterized by mortality. We present a case of a 18 year-old young showing remission by early diagnosis. The patient was admitted to emergency department with symptoms and findings of atypic pneumonia with bloody sputum. Chest radiography detected patchy alveolar opacities (Figure A). An ampric antibacterial treatment was given including macrolide, and bronchodilators because of bronchospasm. The patient was suspected for goodpasture s syndrome (GPS). Anti-glomerular basement membrane (AGBM) antibodies test was send. He developed massive alveolar haemorrhage in the resolution phase of atypic pneumonia. Laboratory examination revealed proteinuria of 20 mg/ dl, anemia Hb of 8 g/dl, hematocrit of 25%, microscopic hematuria of 350 erythrocite /HPF. AGBM antibodies was found as positive. GPS was diagnosed. Early immunosuppressive treatment with pulse methylprednisolone and cyclophosphamide and plazmaferez was started. Noninvasive positive pressure ventilation (NPPV) was used for severe hypoxemia. Haemolytic anemia and thrombocytopenia developed under plasmaphresis treatment. Early treatment resulted with remmission. In conclusion, the current case showed that Goodpasture s syndrome may have a favorable prognosis with early diagnosis and proper treatments including NPPV.

Özet

Goodpasture sendromu alveolar hemoraji, progresif glomerulonefrit ve antiglomeruler bazal membran antikorları ile kendini gösterir. Sıklıkla mortal olabilen bir hastalıktır. 18 yaşında erken tanı ile remisyon sağlanan bir erkek olguyu bildiriyoruz. Vaka acil servise atipik pnönomi belirti ve bulguları ve balgamında kan varlı- ğı ile başvurdu. Göğüs grafisi yama tarzında alveolar opasiteler gösterdi (Figür A). Profilaktik makrolid grubu antibiyoterapi ve bronkospazm için bronkodilatör tedavi verildi. Vakada Goodpasture sendromun (GPS)dan şüphelenildi. Anti-glomerüler bazal membran (AGBM) antikor testi gönderildi. Atipik pnömoni rezolüsyon döneminde olguda massif alveolar hemoraji gelişti. Laboratuar incelemesi proteinüri 20 mg/dl, Anemi 8 g/dl, Hemotorit %25, mikroskobik hematüri 350/HPF gösterdi. AGBM antikor testi pozitif bulundu. GPS tanısı konuldu. Olguya erken dönemde metilprednizolon ve siklofosfamid ile immunsupresif ve plazmaferez tedavisi baş- landı. Şiddetli hipoksemi için noninvaziv pozitif basınçlı ventilasyon (NPBV) uygulandı. Plazmaferez tedavisi sürerken hemolitik anemi ve trombositopeni gelişti. Erken başlanan tedavi remisyonla sonuçlandı. Sonuç olarak GPS erken tanı ve NİPBVu içeren uygun tedavilerle iyi bir prognoza sahip olabilir.

🔖

Cite This Article

SERTOĞULLARINDAN, B., ESEN, R., BEGENİK, H., ÖZBAY, M. B., CİFTÇİ, R. (2022). Goodpasture Sendromu Nedeniyle Alveolar Hemoraji Gelişen Bir Olguda Noninvaziv Pozitif Basınçlı Ventilasyon Kullanımı. Journal of Clinical and Analytical Medicine, Cilt: 6 - Sayı: 4, 504–506. https://ajindex.com/articles/561043

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Peto P, Salama AD. Update on antiglomerular basement membrane disease. Curr Opin Rheumatol 2011;23(1):32-7
  2. Sakoda C, Kusaba T, Adachi T, Sonomura K, Kimura T, Nakayama M et al. A case of Goodpasture syndrome positive for anti-GBM antibody and MPO-ANCA complicated by a variety of serious infections. Clin Nephrol 2011;75(4):384-8
  3. Casian A, jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin respir crit care med 1011;32(3):335-45
  4. Salam N, Rekzi H, Fadili W, Hachim K, Ramdani B. Goodpasture’s Syndrome – Four case reports. Saudi J Kidney Dis Transplant 2007;18(2):235-8
  5. Salama AD, Levy JB, Lightstone L, Pusey CD. Goodpasture’s disease. Lancet 2001;358(9290):1374
  6. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma-exchange in the treatment of Goodpasture’s syndrome. Lancet 1976;307(7962):711-5
  7. Antonelli M, Conti G, Bufi M Costa MG, Lappa A, Rocco M et al. Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial. JAMA 2000;283(2):235-41
  8. Ferrer M, Esquinas A, Leon M, Gonzalez G, Alarcon A, Torres A et al. Noninvasive ventilation in severe acute hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003;168(12):1438-44
  9. Antonelli M, Conti G, Esquinas A, Montini L, Maggiore SM, Bello G et al. A multiple-center survey of the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. Crit Care Med 2007;35(1):18-25
  10. Smith JW, Weinstein R, Hillyer KL. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003; 43(6):820-2.